The potential economic value of a Staphylococcus aureus vaccine for neonates.

TitleThe potential economic value of a Staphylococcus aureus vaccine for neonates.
Publication TypeJournal Article
Year of Publication2010
AuthorsLee BY, Ufberg PJ, Bailey RR, Wiringa AE, Smith KJ, Nowalk AJ, Higgins C, Wateska AR, Muder RR
JournalVaccine
Volume28
Issue29
Pagination4653-60
Date Published2010 Jun 23
ISSN1873-2518
KeywordsComputer Simulation, Cost-Benefit Analysis, Humans, Infant, Newborn, Methicillin-Resistant Staphylococcus aureus, Models, Economic, Staphylococcal Infections, Staphylococcal Vaccines
Abstract

The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (or=1%).

DOI10.1016/j.vaccine.2010.04.069
Alternate JournalVaccine
PubMed ID20472028
PubMed Central IDPMC2896294
Grant List1U54GM088491-0109 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
U54 GM088491-01 / GM / NIGMS NIH HHS / United States
Publication Categories: